These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25217405)

  • 1. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
    Atrio J
    J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
    [No Abstract]   [Full Text] [Related]  

  • 2. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'.
    Lanza LL; McQuay LJ; Rothman KJ; Bone HG; Kaunitz AM; Harel Z; Ataher Q; Ross D; Arena PL; Wolter KD
    J Fam Plann Reprod Health Care; 2013 Oct; 39(4):306. PubMed ID: 24062508
    [No Abstract]   [Full Text] [Related]  

  • 5. Anaphylaxis from medroxyprogesterone acetate.
    Selo-Ojeme DO; Tillisi A; Welch CC
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot medroxyprogesterone acetate in teens: A risk for bone health?
    Bachrach LK; Cundy T; Ott SM
    Pediatrics; 2000 Nov; 106(5):1137-8. PubMed ID: 11061788
    [No Abstract]   [Full Text] [Related]  

  • 8. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Berger RE
    J Urol; 2005 Sep; 174(3):941. PubMed ID: 16093999
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombocytopenic purpura with depot medroxyprogesterone acetate and subsequent use of contraceptive implant: making decisions in the absence of evidence.
    Holman R; Stephen G
    J Fam Plann Reprod Health Care; 2005 Oct; 31(4):333-4. PubMed ID: 16274569
    [No Abstract]   [Full Text] [Related]  

  • 10. RETIRED: Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa).
    Black A; ;
    J Obstet Gynaecol Can; 2006 Apr; 28(4):305-308. PubMed ID: 16776909
    [No Abstract]   [Full Text] [Related]  

  • 11. Subcutaneous depo-medroxyprogesterone acetate.
    Cameron S
    J Fam Plann Reprod Health Care; 2013 Apr; 39(2):75-7. PubMed ID: 23493590
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate.
    Hapgood JP
    Endocrinology; 2013 Mar; 154(3):985-8. PubMed ID: 23429710
    [No Abstract]   [Full Text] [Related]  

  • 13. 'Black box' warning added to contraceptive injection.
    FDA Consum; 2005; 39(2):3. PubMed ID: 16124078
    [No Abstract]   [Full Text] [Related]  

  • 14. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium.
    Miller L; Patton DL; Meier A; Thwin SS; Hooton TM; Eschenbach DA
    Obstet Gynecol; 2000 Sep; 96(3):431-9. PubMed ID: 10960638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Review: Mechanisms of HIV Transmission in Depo-Provera Users: The Likely Role of Hypoestrogenism.
    Hickey M; Marino JL; Tachedjian G
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):1-7. PubMed ID: 26761267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: adolescents who lost 5% or more from baseline vs. those who lost less than 5%.
    Harel Z; Wolter K; Gold MA; Cromer B; Stager M; Johnson CC; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Burkman R; Nelson A; Marshall S; Bachrach LK
    Contraception; 2010 Dec; 82(6):503-12. PubMed ID: 21074012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Ziaei S; Ninavaei M; Faghihzadeh S
    Acta Obstet Gynecol Scand; 2004 Oct; 83(10):909-11. PubMed ID: 15453884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria.
    Hu E; Ikeako LC; Obiora-Okafor NC
    Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.